CMS Must Work Harder to Get New Drugs and Devices Covered Quickly, House Members Say
Medicare needs to up its game when it comes to approving coverage for new drugs and devices, witnesses and members of Congress agreed Tuesday at a House hearing. “Despite the historic advancements in treatments for Alzheimer’s disease, the Biden administration has decided to limit access to these therapies through onerous coverage policies that require patients […]
Congressional Probe of Alzheimer’s Drug Approval Finds Fault With FDA Actions
The FDA broke with its own protocols in reviewing and subsequently approving Alzheimer’s drug aducanumab (Aduhelm), by inappropriately collaborating with drugmaker Biogen on briefing documents, holding unreported meetings, and failing to gain internal consensus before engaging in such collaborations, according to an in-depth congressional investigation of the interactions between the agency and the drugmaker. The […]